Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine.
Karama AslehAna LluchAngela GoytainCarlos Henrique BarriosXue Qi WangLaura TorrecillasDongxia GaoManuel Ruiz BorregoSamuel C Y LeungJose BinesAngel L Guerrero-ZotanoJosé Angel García-SaenzJuan Miguel CejalvoJesus HerranzRoberto TorresJuan R De la Haba-RodríguezFrancisco AyalaHenry L GómezFederico RojoTorsten O NielsenMiguel MartinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
In this prespecified correlative analysis of the GEICAM/CIBOMA trial, PAM50 non-basal status identified early-stage TNBC patients most likely to benefit from capecitabine.
Keyphrases
- early stage
- phase iii
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- phase ii study
- prognostic factors
- locally advanced
- study protocol
- squamous cell carcinoma
- randomized controlled trial
- open label
- phase ii
- patient reported outcomes
- sentinel lymph node
- lymph node
- patient reported
- neoadjuvant chemotherapy